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ABSTRACT
Background: Knowledge about the variability in the request of cal-
cium-phosphate metabolism laboratory tests in primary care is important to 
design strategies to improve health system efficiency. Aim: To compare the 
inter-practice variability in calcium-phosphate metabolism laboratory tests 
requested by general practitioners from diverse regions across Spain. Material 
and Methods: One hundred and forty one clinical laboratories were invited to 
participate in an observational cross-sectional study. They informed the number 
of serum calcium, phosphate, parathyroid hormone and 25-hydroxyvitamin D 
requested by general practitioners. Appropriateness indicators were calculated as 
number of test requests per 1,000 inhabitants and ratio of related tests requests. 
The differences according to hospital setting, region and type of management 
were analyzed. Results: We recruited 76 laboratories (17,679,195 inhabitants). 
General practitioners requested 3,260,894 calcium-phosphate metabolism tests. 
The rate of request ranged from 2.97 per 1,000 inhabitants for 25-hydroxyvitamin 
D to 98.89 per 1,000 inhabitants for calcium. The rates of request for calcium, 
phosphate, parathyroid hormone in some areas were 30, 100 and 340 times hi-
gher than in other areas. Parathyroid hormone and 25-hydroxyvitamin D were 
highly requested in private management areas. There were also differences in 
phosphate, parathyroid hormone and 25-hydroxyvitamin D requesting between 
regions across Spain. Conclusions: The high variability observed is difficult to 
explain by differences in patient case mix between regions. Depending on the 
area, calcium could be under requested to detect primary hyperparathyroidism. 
(Rev Med Chile 2016; 144: 990-997) 
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Solicitud de pruebas de laboratorio para el 
diagnóstico y manejo de los desórdenes del 
metabolismo fosfocálcico en España
Objetivo: Conocer la variabilidad en la solicitud de pruebas de laboratorio en 
atención primaria es importante para diseñar estrategias que mejoren la eficiencia 
del sistema de salud. La propuesta de este estudio fue comparar la variabilidad 
en la solicitud de pruebas para la evaluación del metabolismo fosfocálcico por 
médicos de atención primaria de diversas regiones de España. Material y 
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Hypercalcemia can be caused by many disorders, but is most commonly due to neoplastic disease in inpatients and to 
primary hyperparathyroidism (PHPT) in outpa-
tients1,2. PHPT is the third most common endo-
crine disease after diabetes and thyroid diseases3. 
Due to its mild symptoms, the disorder can be 
detected in primary care, through an unexpected 
hypercalcaemia. It is crucial to diagnose this highly 
prevalent disorder early in its clinical course, as 
timely treatment delays progression and prevents 
its devastating complications, thus improving 
prognosis4-6. 
Test requesting inappropriateness is a major is-
sue for a healthcare system7,8; test under requesting 
results in misdiagnosis, on the other hand, over 
requesting produces unnecessary expenses, but 
even physical and psychological patient adverse 
effects8-11.
There is high variability in the request of 
calcium (S-calcium) and phosphate (S-phos-
phate), between different regions, and referring 
physicians12-16. In certain areas, S-calcium is un-
der-requested to detect asymptomatic PHPT14,15. 
Currently, through studies investigating regional 
and geographical differences in test request12,13,17,18, 
we can detect requesting inappropriateness, and 
deduce the root causes of such potential problem. 
The aim of this research was to study the 
inter-practice variability in calcium-phosphate 
metabolism laboratory tests requested by General 
Practitioners (GPs) in Spain to investigate the 
degree in requesting appropriateness and deduce 
its potential causes.
Materials and Methods
Data collection 
Encouraged by the previous pilot studies in the 
Valencian Community12 and all around Spain13-18 
a call for data was posted via email. Spanish labo-
ratories willing to participate in the study were 
invited to fill out an enrollment form and submit 
their results online. A total of 141 laboratories were 
invited to participate. We obtained production 
statistics (number of tests requested by GPs for the 
year 2012 from laboratories at different hospitals 
from diverse regions across Spain. Every patient 
seen in any primary care center (PCC) of any of 
these health departments, regardless of the reason 
for consultation, gender or age, was included in 
the study. Each participating laboratory was re-
quired to be able to obtain patient data from local 
databases and to provide organizational data (i.e. 
population served, public/private management, 
location). S-calcium, S-phosphate, albumin, para-
thyroid hormone (PTH) and 25-hydroxyvitamin 
D [25(OH)D] test requesting were examined in a 
cross-sectional study. 
Data processing 
After collecting the data, two types of appro-
priateness indicators were calculated: every test 
request per 1,000 inhabitants and ratio of related 
Método: Se invitó a participar a 141 laboratorios clínicos de diversas regiones 
españolas. Completaron una encuesta con el número de determinaciones de calcio, 
fósforo, hormona paratiroidea y 25-hidroxivitamina D solicitadas por médicos 
de atención primaria de sus áreas. Se calcularon las tasas en relación a la pobla-
ción y se construyeron indicadores de adecuación. Los resultados se compararon 
por características del hospital, región y tipo de gestión. Resultados: Obtuvimos 
los datos de 76 laboratorios (17.679.195 habitantes). Los médicos de atención 
primaria solicitaron 3.260.894 pruebas de metabolismo fosfocálcico. La tasa de 
solicitud varió de 2,97 por 1.000 habitantes de 25-hidroxivitamin D a 98,89 por 
1.000 habitantes de calcio. Las tasas de calcio, fósforo, hormona paratiroidea 
en algunas áreas fue 30, 100 y 340 veces más alta respecto a otras. Hormona 
paratiroidea y 25-hidroxivitamina D fueron más solicitadas significativamente 
en hospitales con gestión privada. También hubo diferencias en fósforo, hormona 
paratiroidea y 25-hidroxivitamina D solicitas entre distintas regiones de España. 
Discusión: La alta variabilidad observada es difícil de explicar por las diferencias 
de las características de los pacientes. Dependiendo de la región podría haber una 
infra solicitud para la detección del hiperparatiroidismo primario.
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tests requests (S-phosphate/S-calcium; 25(OH)D/
PTH). In order to explore the inter-practice varia-
bility, another indicator, the “index of variability”, 
was calculated as follows: top decile divided by 
bottom decile (90th percentile/10th percentile). 
We calculated if the rate of test requests was 
different according to the setting (rural, urban, 
or rural-urban) of the hospital and whether the 
institution had a public or private management.
Finally, the indicators results obtained in the 
laboratories in the three regions with the highest 
number of departments participating in the study 
were compared between them and to the pooled 
results of the remaining regions in order to esta-
blish whether there were regional differences in 
the requesting patterns.
Statistical methods 
The statistical treatment of the calculated 
data included: the distribution, the mean, 95% 
confidence level for the mean, standard deviation, 
median and interquartile range. The analysis of the 
distribution of the number of indicators results 
was conducted by way of the Kolmogorov-Smir-
nov test.
The differences in indicators results according 
to the hospital characteristics and per region were 
calculated by way of the Mann-Whitney U or 
Kruskal-Wallis test analysis, as appropriate. 
A two-sided p ≤ 0.05 rule was utilized as the 
criterion for rejecting the null hypothesis of no 
difference.
Results 
We obtained production statistics from 76 
laboratories at different hospitals from diverse 
regions across Spain. 17,679,195 patients (37.8% 
of the Spanish population) were included in the 
study, from 13 Communities (Valencian Com-
munity, 23 laboratories and 4,848,900 patients 
(96.9% of the Valencian Community population); 
Andalucía, 12 laboratories and 3,849,485 patients 
(37.8% of Andalucía population); Castilla y León, 
9 laboratories and 1,695,916 patients (67.1% of 
Castilla y León population) and other region, 32 
laboratories and 7,284,889 patients). GPs reques-
ted 3,260,894 calcium-phosphate metabolism 
laboratory tests. A summary of the organizational 
data of the different laboratories that participated 
in the study is showed in Table 1.
Table 2 shows the descriptive statistical analysis 
and the variability index for the indicator results. 
The rates of request for S-calcium, S-phosphate 
and PTH in some areas were 30, 100 and 340 times 
higher than in other areas respectively.
GPs requested albumin to the 76 laboratories. 
However, only 17 laboratories additionally provi-
ded calcium corrected per albumin. 
Table 3 compares the appropriateness indica-
Table 1. Descriptive characteristics of the hospitals/health care departments that participated 
in the study
Descriptive characteristics Data
areas (n) 76
subjects (n) 17,679,195
Population/area [mean (ci95%)] 232,621 (200,099.8-265,142.2)
location [n (%)] valencian community 23 (30.3%)
andalucía 12 (15.8%)
castilla y león   9 (11.8%)
other región      (42.1%)
type of Management [n (%)] Public 70 (92.1%)
Private   6   (7.9%)
setting [n (%)] urban 15 (19.7%)
rural   3   (3.9%)
urban-rural 58 (76.3%)
ci: confidence interval of the mean.
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Table 4. Differences of appropriateness indicators results obtained at the laboratories  
of the different regions of Spain
Tests/1,000 inhabitants
(mean ± SD)
Ratio of related tests
 (mean ± SD)
S-calcium S-phosphate PTH 25(OH)D S-phosphate/ 
S-calcium
25(OH)D/PTH
v   91.93 ± 76.01   52.70 ± 48.50 5.71 ± 5.97* 6.11 ± 6.26* 0.604 ± 0.250 0.852 ± 0.303
a 117.08 ± 106.75   39.87 ± 41.36 2.41 ± 3.44 1.48 ± 2.41 0.415 ± 0.292 0.898 ± 0.626
cl 119.83 ± 51.91 109.34 ± 56.66* 1.07 ± 0.64 0.78 ± 0.50 0.886 ± 0.090* 1.528 ± 2.180
or   91.18 ± 56.35   61.98 ± 53.12 1.83 ± 1.57 1.79 ± 2.62 0.637 ± 0.271 1.481 ± 1.705
*Kruskal-Wallis test (p value < 0.05); legend: vc: valencian community; a: andalucía; cl: castilla y león; or: other regions. 
serum calcium (s-calcium); phosphate (s-phosphate); parathyroid hormone (PtH) and 25-hydroxyvitamin d [25(oH)d]. s-phos-
phate request in cl was significantly higher than in  a; PtH and 25(oH)d in v were significantly higher than a, cl and or; 
s-phosphate/ s-calcium in cl significantly higher than a, v and or.
Table 2. Descriptive statistical analysis and the variability index
 Range Mean CI95% Median IQR Variability 
Index
tests/1,000 
inhabitants
s-calcium 11.37-334.10 98.89 82.55-115.23 88.38 80.96   7.63
s-phosphate 2.29-230.66 61.29 49.15-73.43 45.17 65.29 16.82
PtH 0.05-17.77   3.01 2.07-3.94   1.55   1.89 23.15
25oHd 0.03-21.19   2.97 1.93-4   1.11   1.79 51.65
albumin 0.25-231.84 55.38 41.73-69.02 31.20 56.93 31.89
related test 
requested ratios
25oHd/PtH 0.015-9.004 1.336 0.937-1.735 0.861 0.987 14.85
s-phosphate/ s-calcium 0.046-0.993 0.621 0.558-0.685 0.659 0.492   4.62
legend: serum calcium (s-calcium); phosphate (s-phosphate); parathyroid hormone (PtH) and 25-hydroxyvitamin d [25(oH)d].
Table 3. Differences of appropriateness indicators results obtained at the laboratories  
of the different locations and according to the type of management
S-calcium Test per 1,000 inhabitants
(mean±SD)
Ratios of related tests 
(mean±SD)
S-phosphate PTH 25(OH)D S-phosphate/ 
S-calcium
25(OH)D/PTH
location u 131.95 ± 81.30 87.62 ± 48.62   4.37 ± 5.08 5.10 ± 6.53 0.757 ± 0.235 1.014 ± 0.597
r 64.29 ± 25.70 24.57 ± 2.20   1.66 ± 0.82 0.80 ± 0.40 0.428 ± 0.187 0.483 ± 0.096
u-r 92.13 ± 68.42 56.38 ± 53.44   2.72 ± 3.85 2.51 ± 3.75 0.596 ± 0.282 1.469 ± 1.939
Management P 98.51 ± 72.22 59.51 ± 54.44   2.37 ± 3.03† 2.54 ± 4.03† 0.608 ± 0.282 1.395 ± 1.783
Pv 103.31 ± 25.12 81.98 ± 29.92 10.42 ± 7.11 7.75 ± 6.76 0.781 ± 0.166 0.669 ± 0.356
* Kruskal-Wallis test significative (p < 0.05);  †u-Mann-Whitney test significative (p<0.05).
tors results obtained at the different laboratories 
according to their setting and type of management. 
PTH and 25(OH)D that were higher requested in 
areas with private management.  
Table 4 compares the number of requests per 
1,000 inhabitants in the different regions. There 
were no differences in S-calcium requesting, 
however S-phosphate was higher requested in 
Castilla y León  when compared to Andalucía. 
PTH and 25(OH)D were over requested in Va-
lencian Community when compared to Castilla 
y León, Andalucía and the remaining regions. 
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Discussion
There were significant differences in the re-
quest of calcium-phosphate metabolism labora-
tory tests, as seen in prior investigations12,13. The 
variability observed for S-calcium in the study was 
from 11.37 to 334.10 tests per 1,000 inhabitants. 
This variability could be explained in the diffe-
rent areas by case mix variations, or the possible 
variability in the patient demographic. However 
the differences observed between areas are so high 
that it was probably caused by additional reasons. 
Hypercalcaemia is a highly prevalent condi-
tion19, up to of 3.9% of the general population20. 
Eleven requests of S-calcium tests per 1,000 inha-
bitants, as in certain areas, indicate that, on ave-
rage, every patient would get a test ordered every 
100 years. In this scenario, S-calcium may be under 
requested for two main reasons. First, S-calcium 
is crucial to detect asymptomatic PHPT14. Second 
S-calcium testing does not usually yield false po-
sitive results with a proper sampling technique21. 
At least 88% of patients with hypercalcaemia will 
turn out to have an underlying disorder during a 
10-year follow-up period, which makes necessary 
careful investigation of such subjects22. 
Asymptomatic PHPT is usually detected 
in health screenings. With the introduction of 
automated S-calcium measurement with multi-
channel continuous-flow analyzers in the 1970s, 
this silent disease began to be detected23. At 
that time, unexpected high S-calcium values on 
serum biochemical screening contributed to the 
diagnosis of 250 new cases of PHPT per million 
inhabitants per year24. Then, the disappearance 
of the multichannel analyzers and simultaneous 
introduction of random access analyzers, that in 
general would benefit the appropriate laboratory 
test requesting by demanding and measuring only 
those tests related to a certain diagnosis, resulted 
in S-calcium under requesting and, hence, a 
decreased detection of asymptomatic PHPT25, 26. 
PHPT became a not so infrequent disease that was 
often overlooked by physicians27. In fact, with the 
disappearance of multichannel continuous-flow 
analyzers S-calcium is at risk of being the “forgo-
tten test”, and strategies must be encouraged to 
increase its request for a correct PHPT detection14. 
The prevalence of PHPT in Spain varies be-
tween 1 and 4/1,000 in the general population28. 
Lately, thanks to the establishment of PHPT 
screening strategies, it is even increasing14. De-
pending on the criteria used to define PHPT, the 
prevalence of the disorder in older women ranges 
from 3.6% to 13.9%, making it really important 
to define hypercalcemia as a first step to detect 
the disorder29. Total calcium (S-calcium) occurs 
in plasma in free form, “ionized calcium”, and in 
complex bound form, especially with albumin30. 
It is only ionized calcium which is physiologi-
cally relevant, and this would be the fraction to 
be measured. Methods are available, but they 
require specially analyzers and rapid anaerobic 
handling of the sample. So, in most clinical 
situations disturbances in calcium metabolism 
have to be assessed from changes in the S-calcium 
concentration. As ionized calcium, the biologi-
cally active, is unstable in PCCs samples, it is 
crucial the calculation of total calcium corrected 
per albumin. It is true that calcium binding to 
albumin is influenced by pH and hence by stasis, 
but within the range found in current clinical 
practice the proportion of S-calcium which is 
bound varies little31. However, as showed in our 
study results, only 22% of laboratories reported 
albumin-corrected calcium. 
The interest of measuring S-phosphate is 
always related to S-calcium. The request of 
S-phosphate ranged from a one to one ratio when 
compared to S-calcium request, to almost zero. 
S-phosphate should be probably only requested 
based on algorithms after abnormal values of 
S-calcium, as performed with aminotransferases32 
or thyroid hormones33.
The variability in PTH and 25(OH)D reques-
ting was even higher than that for S-calcium and 
S-phosphate and is very difficult to interpret, 
mainly for two reasons. First, we do not know if 
the different request patterns could be explained 
by the different implication of GPs in the manage-
ment of calcium-phosphate metabolism disorders 
in the different areas. Second, there are no prior 
studies regarding PTH and 25(OH)D request in 
primary care to compare with. Both tests were 
over requested in areas with private management. 
This could be explained by the fact that this type 
of management is new, and physicians working 
in such areas may be more prone to manage 
calcium-phosphate metabolism disorders. The 
fact that these areas with private management 
are located in Valencian Community could 
explain or at least could contribute to the over 
laboratory requests for calcium-Phosphate disorders - M. salinas et al
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request of such tests in Valencian Community, 
when compared to other regions. Additionally, it 
seems plausible that centers that are interested in 
hyperparathyroid disorders request more of all 
these markers. There was a high variability in the 
ratio 25(OH)D/PTH between the different areas, 
which ranged from 0.015 to 9. More studies are ne-
cessary to explain those striking results. Along the 
last years, hypovitaminosis D has been associated 
with many clinical condition (immunology and 
oncology disorders) there was a spread of 25(OH)
D test requests among different centers other than 
those specialized in metabolic bone disease and 
also among general practitioners34. 
The strength of this study includes the na-
tional representation of the studied population; 
this allows us to provide accurate estimates of 
indicator calculation. Nonetheless, the study 
had certain limitations. First, the differences in 
calcium-phosphate metabolism laboratory tests 
request between health care regions in Spain 
could be partly explained by case mix variations 
in the different areas, or the possible variability in 
the patient population. Second, we did not take 
into account the differences in blood sampling 
techniques and the distribution of age, gender, 
medication and body mass index of the subjects 
at the different participating laboratories. Third, 
we did not evaluate the request of ionized calcium, 
because we did not get those data, and another 
potential indicators as S-calcium/PTH Also, the 
variability showed in our study could be explained 
by regional different degrees of awareness in the 
management of calcium-phosphate disorders in 
primary care. Finally, it is difficult to know whe-
ther there is over or under request without clinical 
patient data.
In all, there was high variability in the request 
of calcium-phosphate tests in almost half of 
the Spanish population, difficult to explain by 
differences in patient case mix between regions. 
S-calcium was probably under requested in some 
areas to detect silent diseases such as PHPT. Great 
efforts must be done from every stakeholder that 
intervenes in calcium-phosphate metabolism 
disorders, mainly S-calcium and PTH requests 
should be homogeneous, as they are basic for 
PHPT diagnosis.
Acknowledgments: Members of the REDCON-
LAB working group are the following (in alpha-
betical order): Alfonso Pérez-Martínez (Hospital 
Morales Meseguer); Amparo Miralles (Hospital de 
Sagunto); Ana Santo-Quiles (Hospital Virgen de la 
Salud, Elda); Ángela Rodríguez-Piñero (Hospital 
Universitario de Móstoles); Ángeles Giménez-Ma-
rín (Hospital de Antequera); Antonio Buño-Soto 
(Hospital La Paz, Madrid); Antonio Gómez del 
Campo (Complejo Asistencial de Ávila); Anto-
nio León-Juste (Hospital Juan Ramón Jiménez, 
Huelva); Antonio Moro-Ortiz (Hospital de Valme, 
Sevilla); Begoña Laiz (Hospital Universitario y Po-
litécnico La Fe de Valencia); Berta González-Ponce 
(Hospital Da Costa, Burela); Carmen Hernando 
de Larramendi (Hospital Severo Ochoa de Le-
ganés); Carmen Vinuesa (Hospital de Vinaros); 
Cesáreo García-García (Hospital Universitario 
de Salamanca); Concepción Magadán-Núñez 
(Hospital Arquitecto Marcide, El Ferrol); Con-
suelo Tormo (Hospital General Universitario de 
Elche); Cristina Santos-Rubio (Hospital Río Tinto, 
Huelva); Cristóbal Avivar (Hospital de Poniente, 
El Ejido); Diego Benítez Benítez (Hospital de 
Orihuela); Eduardo Sánchez-Fernández (Hospital 
del Vinalopo, Elche); Emilia Moreno-Noguero 
(Hospital Can Misses); Enrique Rodríguez-Borja 
(Hospital Clínico Universitario de Valencia); 
Esther Roldán-Fontana (Hospital La Merced. 
Area de Gestión Sanitaria Sevilla Este); Fco. Javier 
Martín Oncina (Hospital Virgen del Puerto de 
Plasencia, Cáceres); Félix Gascón (Hospital Valle 
de los Pedroches, Pozoblanco); Fernando Rodrí-
guez Cantalejo (Hospital Universitario Reina Sofía 
de Córdoba); Fidel Velasco Pena (Hospital Virgen 
de Altagracia, Manzanares); Francisco Miralles 
(Hospital Lluis Alcanyis, Xàtiva); Goitzane Mar-
caida (Consorcio Hospital General Universitario 
de Valencia); Marta Barrionuevo (Hospital Uni-
versitario Principe de Asturias, Alcalá de Hena-
res); Inmaculada Domínguez-Pascual (Hospital 
General Universitario Virgen del Rocío, Sevilla); 
Isidoro Herrera Contreras (Complejo Hospita-
lario de Jaén); José Antonio Ferrero (Hospital 
General de Castellón); José Luis Barberà (Hospital 
de Manises); José Luis Quilez Fernández (Hospital 
Universitario Reina Sofía de Murcia); Jose Luis 
Ribes-Vallés (Hospital de Manacor); José Miguel 
González Redondo (Hospital Santiago Apóstol de 
Miranda de Ebro); José Sastre (Hospital Virgen 
de los Lirios, Alcoy); José Vicente García-Lario 
(Hospital Virgen de las Nieves, Granada); Juan 
Ignacio Molinos (Hospital Sierrallana, Torre-
laboratory requests for calcium-Phosphate disorders - M. salinas et al
rev Med chile 2016; 144: 990-997
996
artículo de investigación
lavega); Juan Molina (Hospital Comarcal de La 
Marina, Villajoyosa); Juan Ramón Martínez-In-
glés (Hospital General Universitario Santa Lucía, 
Cartagena); Julián Díaz (Hospital Francesc de 
Borja, Gandia); Laura Navarro Casado (Complejo 
Hospitalario Universitario de Albacete); Leopoldo 
Martín-Martín (Hospital General de La Palma); 
Lola Máiz Suárez (Hospital Universitario Lucus 
Augusti, HULA, Lugo); Luís Rabadán (Complejo 
Asistencial de Soria); M. Dolores Calvo (Hospital 
Clínico de Valladolid); M. Amalia Andrade-Olivie 
(Hospital Xeral-Cies, CHU Vigo); M. Ángeles 
Rodríguez-Rodríguez (Complejo Asistencial de 
Palencia); M. Carmen Gallego Ramírez (Hos-
pital Rafael Méndez, Lorca); M. Mercedes He-
rranz-Puebla (Hospital Universitario de Getafe); 
M. Victoria Poncela-García (Hospital Universita-
rio de Burgos); Mª José Baz (Hospital de Llerena, 
Badajoz); Mª José Martínez-Llopis (Hospital de 
Denia); Mª Teresa Avello-López (Hospital San 
Agustín, Avilés); Mabel Llovet (Hospital Verge 
de la Cinta, Tortosa); Mamen Lorenzo (Hospital 
de Puertollano); Marcos López-Hoyos (Hospital 
Universitario Marqués de Valdecilla); María José 
Zaro (Hospital Don Benito-Villanueva); María 
Luisa López-Yepes (Hospital Virgen del Castillo 
de Yecla); Mario Ortuño (Hospital Universitario 
La Ribera); Marisa Graells (Hospital General 
Universitario de Alicante); Marta García-Collía 
(Hospital Ramón y Cajal, Madrid); Martín Yago 
(Hospital de Requena); Mercedes Muros (Hos-
pital Nuestra Señora de la Candelaria, Tenerife); 
Nuria Estañ (Hospital Dr. Peset, Valencia); Nuria 
Fernández-García (Hospital Universitario Río 
Hortega, Valladolid); Pilar García-Chico Sepúl-
veda (Hospital General Universitario de Ciudad 
Real); Ricardo Franquelo (Hospital Virgen de la 
Luz de Cuenca); Ruth González Tamayo (Hospital 
de Torrevieja); Silvia Pesudo (Hospital La Plana); 
Vicente Granizo-Domínguez (Hospital Universi-
tario de Guadalajara); Vicente Villamandos-Nicás 
(Hospital Santos Reyes, Aranda del Duero); Vidal 
Pérez-Valero (Hospital Regional de Málaga).
References
1.  Evans RA. Hypercalcaemia. What does it signify? Drugs 
1986; 31 (1): 64-74.
2.  Lafferty FW. Differential diagnosis of hypercalcemia. J 
Bone Miner Res 1991; 6 (2): S51-9.
3.  Harrison BJ, Wheeler MH. Asymptomatic primary 
hyperparathyroidism. World J Surg 1991; 15 (6): 724-9.
4.  Weber T, Eberle J, Messelhäuser U, Schiffmann L, 
Nies C, Schabram J, et al. Parathyroidectomy, elevated 
depresion scores, and suicidal ideation in patients with 
primary hyperparathyroidism. Results of prospective 
multicenter study. JAMA Surg 2013; 148 (2): 109-15.
5.  Walker MD, Rundek T, Homma S, Di Tullio M, Iwata S, 
Lee JA, et al. Effect of parathyroidectomy on subclinical 
cardiovascular disease in mild primary hyperparathyroi-
dism. Eur J Endocrinol 2012; 167 (2): 277-85. 
6.  Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane 
E, Siris E, et al. The natural history of primary hyperpa-
rathyroidism with or without parathyroid surgery after 
15 years. J Clin Endocrinol Metab 2008; 93 (9): 3462-70.
7.  van Walraven C, Naylor CD. Do we know what inappro-
priate laboratory utilization is? A systematic review of 
laboratory clinical audits. JAMA 1998; 280 (6): 550-8.
8.  Salinas M, López-Garrigós M, Uris J, Leiva-Salinas C, 
Pilot Group of the Appropriate Utilization of Labora-
tory Tests (REDCONLAB) working group. A study of 
the differences in the request of glycated hemoglobin in 
primary care in Spain: A global, significant, and poten-
tially dangerous under-request. Clin Biochem 2014; 47 
(12): 1104-7.
9. Rang M. The Ulysses syndrome. Can Med Assoc J 1972; 
106 (2): 122-3.
10.  Salinas M, López-Garrigós M, Leiva-Salinas C. False 
positive results: The imaginary invalid syndrome. Aten 
Primaria 2013; 45 (10): 542.
11.  Salinas M, López-Garrigós M, Flors L, Leiva-Salinas C. 
Laboratory false-positive results: a clinician responsibi-
lity or a shared responsibility with requesting clinicians? 
Clin Chem Lab Med 2013; 51 (9): e199-200.
12.  Salinas M, López-Garrigós M, Díaz J, et al. Regional 
variations in test requiring patterns of general practi-
tioners in Spain. Ups J Med Sci 2011; 116 (4): 247-51.
13.  Salinas M, López-Garrigós M, Tormo C, Ortuño M, 
Yago M, Laíz B, et al. Primary care use of laboratory 
tests in Spain: measurement through appropriateness 
indicators. Clin Lab 2014; 60 (3): 483-90.
14.  Salinas M, López-Garrigós M, Pomares F, Lugo J, Asen-
cio A, López-Penabad L, et al. Serum calcium (S-Ca), 
the forgotten test: preliminary results of an appropria-
teness strategy to detect primary hyperparathyroidism 
(pHPT). Bone 2013; 56 (1): 73-6.
15.  Dalemo S, Hjerpe P, Ohlsson H, Eggertsen R, Merlo J, 
Boström KB. Variation in plasma calcium analysis in 
primary care in Sweden-a multilevel analysis. BMC Fam 
Pract 2010; 30 (11): 43.
16.  Dalemo S, Hjerpe P, Boström Bengtsson K. Diagnosis of 
laboratory requests for calcium-Phosphate disorders - M. salinas et al
rev Med chile 2016; 144: 990-997
997
artículo de investigación
patients with raised serum calcium level in primary care, 
Sweden. Scand J Prim Health Care 2006; 24 (3): 160-5.
17.  Larsson A, Palmer M, Hultén G, Tryding N. Large di-
fferences in laboratory utilisation between hospitals in 
Sweden. Clin Chem Lab Med 2000; 38 (5): 383-9.
18.  Salinas M, López-Garrigós M, Uris J; Pilot Group of 
the Appropriate Utilization of Laboratory Tests (RED-
CONLAB) Working Group. Differences in laboratory 
requesting patterns in emergency department in Spain. 
Ann Clin Biochem 2013; 50 (4): 353-9.
19.  Palmer M, Jakobsson S, Akerström G, Ljunghall S. Pre-
valence of hypercalcaemia in a health survey: a 14-year 
follow-up study of serum calcium values. Eur J Clin 
Invest 1988; 18 (1): 39-46.
20.  Christensson T, Hellström K, Wengle B, Alveryd A, 
Wikland B. Prevalence of hypercalcaemia in a health 
screening in Stockholm. Acta Med Scand 1976; 200 (1-
2): 131-7.
21.  Phillips PJ, Pain RW, Hartley TF, Duncan BM, Atkinson 
MJ. Current “corrected” calcium concept rechallenged. 
Clin Chem 1977; 23 (10): 1938-9.
22.  Dalemo S, Eggertsen R, Hjerpe P, Jansson S, Almqvist 
EG, Bengtsson Boström K. Long-term follow-up of 
patients with elevated serum calcium concentrations in 
Swedish primary care. Scand J Prim Health Care 2013; 
31 (4): 248-54.
23.  Bowman WD. Primary hyperparathyroidism. Before 
and after development of routine screening tests. Rocky 
Mt Med J 1972; 69 (5): 53-6.
24.  Mundy GR, Cove DH, Fisken R. Primary hyperpara-
thyroidism: changes in the pattern of clinical presenta-
tion. Lancet 1980; 1 (8182): 1317-20.
25.  Lundgren E, Rastad J, Thrufjell E, Akerström G, Ljun-
ghall S. Population-based screening for primary hyper-
parathyroidism with serum calcium and parathyroid 
hormone values in menopausal women. Surgery 1997; 
121 (3): 287-94.
26.  Press DM, Siperstein AE, Berber E, Shin JJ, Metzger R, 
Monteiro R, et al. The prevalence of undiagnosed and 
unrecognized primary hyperparathyroidism: a popula-
tion-based analysis from the electronic medical record. 
Surgery 2013; 154 (6): 1232-7.
27.  Janssens L, Verbeke V, Petrossians P, Dubois B, Godon 
E, Godon JP, et al. Primary hyperparathyroidism: etio-
logy, diagnosis and treatment. Rev Med Liege 2000; 55 
(11): 977-85.
28.  Muñoz Torres M, Jodar Gimeno E, Reyes García R, 
Martínez Díaz Guerra G, Amado JA, Gaztambide S, et 
al. Results from a national survey on the management of 
primary hyperparathyroidism. J Endocrinol Invest 2012; 
35 (11): 957-63.
29.  Benson L, Ljunghall S, Groth T, Falk H, Hvarfner A, 
Rastad J, et al. Optimal discrimination of mild hyperpa-
rathyroidism with total serum calcium, ionized calcium 
and parathyroid hormone measurements. Ups J Med Sci 
1987; 92 (2): 147-76.
30.  Orrell DH. Albumin as an aid to the interpretation of 
serum calcium. Clin Chim Acta 1971; 35 (2): 483-9.
31.  Phillips P, Pain R. Correcting the calcium. Br Med J 
1977; 1 (6074): 1473.
32.  Lepper PM, Dufour JF. Elevated transaminases-what to 
do if everything was done? Praxis (Bern 1994) 2009; 98 
(6): 330-4.
33.  Srivastava R, Bartlett WA, Kennedy IM, Hiney A, 
Fletcher C, Murphy MJ. Reflex and reflective testing: 
efficiency and effectiveness of adding on laboratory tests. 
Ann Clin Biochem 2010; 47 (3): 223-7.
34.  Brandi ML, Minisola S. Calcidiol [25(OH)D3]: from 
diagnostic marker to therapeutical agent. Curr Med Res 
Opin 2013; 29 (11): 1565-72.
laboratory requests for calcium-Phosphate disorders - M. salinas et al
rev Med chile 2016; 144: 990-997
